SCHEMBL12876348

SCHEMBL12876348

CCOP(=O)(OCC)N(Cc1ccccc1)P(C)(C)=O

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
AOX1 Q06278 1/20 0.47
ACHE P22303 1/20 0.44
NPSR1 Q6W5P4 1/20 0.43
LMNA P02545 3/20 0.43
KCNH2 Q12809 1/20 0.42
ALDH1A1 P00352 3/20 0.41
POLB P06746 2/20 0.40
NPC1 O15118 3/20 0.40
RAB9A P51151 2/20 0.40
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
TSHR P16473 2/20 0.39
HSD17B10 Q99714 2/20 0.39
ALOX15 P16050 1/20 0.39
MAPK1 P28482 1/20 0.39
NR1I2 O75469 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12876347 0.79 LMNA (0.43) ACHENPSR1LMNAALDH1A1POLB
SCHEMBL14900666 0.76 TSHR (0.54) NPSR1ALDH1A1POLBTSHRMAPK1
SCHEMBL7916451 0.75 AOX1 (0.58) AOX1ACHENPSR1LMNAKCNH2
SCHEMBL28351689 0.73 LMNA (0.44) AOX1ACHENPSR1LMNAALDH1A1
SCHEMBL779739 0.72 AOX1 (0.64) AOX1ACHENPSR1LMNAKCNH2
SCHEMBL7718143 0.71 ACHE (0.46) ACHENPSR1LMNAKCNH2ALDH1A1
SCHEMBL1848683 0.71 POLB (0.50) ACHENPSR1LMNAKCNH2ALDH1A1
SCHEMBL15743238 0.71 AOX1 (0.40) AOX1ACHENPSR1LMNAKCNH2
SCHEMBL16352088 0.71 AOX1 (0.40) AOX1ACHENPSR1KCNH2POLB
SCHEMBL15396608 0.71 NPSR1 (0.48) AOX1ACHENPSR1KCNH2POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110034714-A1 METAL COMPLEX COMPOUND, CANCER THERAPEUTIC AGENT COMPOSITION CONTAINING THE METAL COMPLEX COMPOUND AS AN ACTIVE INGREDIENT, AND INTERMEDIATE FOR THE METAL COMPLEX COMPOUND EKIMOTO HISAO 2011-02-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110034714-A1 METAL COMPLEX COMPOUND, CANCER THERAPEUTIC AGENT COMPOSITION CONTAINING THE METAL COMPLEX COMPOUND AS AN ACTIVE INGREDIENT, AND INTERMEDIATE FOR THE METAL COMPLEX COMPOUND NR3C2, NR3C1, MC5R AOX1 2426/4885ACHE 3866/4885NPSR1 2796/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.